Leerink Partners Starts AC Immune SA (ACIU) at Outperform

October 18, 2016 6:44 AM EDT
Get Alerts ACIU Hot Sheet
Price: $11.65 -2.84%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 31 | New: 25
Trade ACIU Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Leerink Partners initiates coverage on AC Immune SA (NASDAQ: ACIU) with a Outperform rating and a price target of $22.00.

Analyst Paul Matteis commented, "AC Immune is a biotechnology company that is focused on developing novel medicines for neurodegenerative disorders. ACIU's lead asset crenezumab – partnered with Roche (Genentech) – is a monoclonal antibody (mAb) that binds multiple sub-types of beta-amyloid. After phase II results that we believe show favorable efficacy trends in milder Alzheimer's Disease (AD) patients, crenezumab has been advanced into a pivotal phase III trial, which is notably exploring a 4-fold higher dose in an earlier, less progressed AD population. ACIU also has a robust drug discovery platform, with additional neurology assets in early development including: ACI-35 (anti-tau vaccine, collaboration with Janssen [JNJ, OP] – ph1b), anti-tau antibody (partnered with Roche – ph1), and ACI-24 (wholly owned abeta vaccine in ph1b/ph1 development for AD and Down syndrome)."

For an analyst ratings summary and ratings history on AC Immune SA click here. For more ratings news on AC Immune SA click here.

Shares of AC Immune SA closed at $14.43 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, New Coverage

Add Your Comment